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Clinical CommunicationsA comparative analysis of changes in
pMDI drug dose delivery before and
after detergent coating using five
antistatic valved holding chambers
Paul Hagedoorna, Wasiq Bawary, PharmDa,
Henderik Willem Frijlink, PhDa, and
Floris Grasmeijer, PhDa,b
Clinical Implications112 Some “antistatic” valved holding chambers are only
poorly antistatic and are, therefore, rather to be used as
ordinary nonantistatic ones (eg, including “priming”). As
a result, antistatic valved holding chambers are
noninterchangeable, which means that switching
between them should be discouraged.TO THE EDITOR:
Pressurized metered dose inhalers (pMDIs) are preferably to
be used in combination with a spacer or valved holding
chamber (VHC). Most notably, this reduces the impact of
actuation-inhalation (“hand-lung”) coordination problems, and
it lowers oropharyngeal deposition as smaller particles are
presented to the patient at a lower velocity.1,2 Spacers and
VHCs may therefore improve compliance and reduce the
chance of local and systemic side effects with the use of
pMDIs.
Although the use of spacers and VHCs is warranted by the
advantages they offer, they also retain a notable fraction of the
drug and hence lower the dose from a pMDI that is delivered
to the patient. Moreover, not only differences in the size,
shape, or construction material, but also differences in the
cleaning and use of spacers and VHCs may greatly affect the
delivered doses from these devices and limit their inter-
changeability.1 This was recently illustrated in a comparison of
4 antistatic VHCs (aVHCs) by Dissanayake et al.3 They
showed that the fine particle dose from a salbutamol pMDI
(Ventolin) may differ by up to a factor 2, even for VHCs that
are comparable in size, shape, and (claimed) antistatic
properties.
Such significant performance differences between similar
aVHCs complicate the drafting of generally applicable guidelines
for their choice and use. For example, nonconducting spacers
and VHCs can be made “antistatic” with a detergent coating (ie,
“primed”) by soaking them in a household detergent solution
followed by drying to the air, also known as “drip-drying.”4 This
lowers drug retention in the VHCs caused by electrostatic
attraction. Understandably, drip-drying is only advocated for
nonconducting VHCs, whereas it is deemed unnecessary for
aVHCs.2 However, if the great performance differences between
aVHCs are caused by differences in their antistatic properties,
drip-drying may be advisable for some of these devices too.
Furthermore, the performance differences may then depend on
the type of drug or the PMDI being used, as drugs and their4formulations may differ in their sensitivity to electrostatic
charging.
To test the supposition that all aVHCs are equally antistatic and
do not need to be coated with a detergent by drip-drying, we
determined the delivered doses of salbutamol (Ventolin 100 mg/
dose label claim) and beclomethasone dipropionate (Qvar 100 mg/
dose label claim) from the Aerochamber Plus Flow-Vu (ACþFV),
the Compact Space Chamber Plus (CSCþ), the InspiraChamber
(IC), the OptiChamber Diamond (OCD), and the Vortex (Vor-
tex); see Figures E1 and E2, and Table E1 (available in this article’s
Online Repository at www.jaci-inpractice.org). These aVHCs
were cleaned in a mild detergent solution and either rinsed with
water (to test their intrinsic antistatic properties) or “drip-dried”
(to test standardized antistatic properties) before every measure-
ment. The “rinsing” method is the cleaning method advocated by
aVHC manufacturers. More methodological details about the
experiment are available in this article’s Online Repository at
www.jaci-inpractice.org.
The “rinsing” method causes a difference in the delivered dose
between the aVHCs of up to a factor 2, with the Vortex and
ACþFV performing significantly better than the CSCþ, IC, and
OCD (Figure 1). Drip-drying particularly increases the delivered
doses from the CSCþ and the IC (.0003 < P < .06, Figure 1),
which indicates that their antistatic properties are suboptimal.
On the contrary, the antistatic properties of the ACþFV, OCD,
and Vortex are optimal, as their delivered doses are minimally
affected by drip-drying. The consistently lower delivered dose
from the OCD than from the ACþFV and Vortex therefore
must be the result of differences other than their antistatic
properties, such as their size, shape, or valve functioning.
It follows from these results that differences in antistatic
properties are an important cause of the large performance dif-
ferences between aVHCs. Therefore, the assumption that
aVHCs do not require drip-drying to improve drug delivery does
not hold true for all of these devices. Furthermore, drip-drying
may greatly improve the interchangeability of aVHCs, as no
significant differences in delivered dose between 4 of 5 aVHCs
tested (ACþFV, CSCþ, IC, and Vortex) were measured after
drip-drying, whereas only 2 (ACþFV and Vortex, or CSCþ and
IC) performed similarly after rinsing. Therefore, as a general
guideline, it seems appropriate to recommend drip-drying, even
for aVHCs, or to at least discourage the switching between them.
It should be noted that a similar delivered dose in this studymay
not equal full in vitro equivalence of the devices. For that, also the
particle size distributions of the delivered doses have to be iden-
tical. It is worth pointing out in this regard that the Vortex does not
result in a finer aerosol of beclomethasone than the pMDI alone,
contrary to the other aVHCs (see Table E2, available in this arti-
cle’s Online Repository at www.jaci-inpractice.org). This may
result in a different deposition pattern. Patient factors will also
affect the deposition pattern, and therefore, the clinical implica-
tions of the observed differences can only be determined by in vivo
studies. Nevertheless, a lower delivered dose with an aVHC
compared with a pMDI alone does not necessarily result in a lower
bioavailability,5,6 as the lung deposition fraction may increase.
The approximate 2-fold difference in delivered dose between
salbutamol and beclomethasone when used with an aVHC can
FIGURE 1. Delivered doses of salbutamol (Ventolin) and beclomethasone (Qvar) from different antistatic valved holding chambers
(aVHCs) after rinsing or drip-drying. The letters denote a significant difference in the delivered dose with the corresponding aVHCs, with
P < .05 (single letter) or P < .005 (double letters). Error bars represent the minimum and maximum values measured (n  4).
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butamol pMDI has a higher plume velocity7 and a larger median
particle size of the aerosol than the beclomethasone pMDI (see
Figure E3 and Table E2, available in this article’s Online Re-
pository at www.jaci-inpractice.org). Both factors likely increase
salbutamol particle deposition in the aVHCs by inertial impac-
tion and sedimentation.
The qualitative similarity of the results obtained with the
different drugs (salbutamol and beclomethasone) from different
pMDI types suggests that the findings from this study are
generally applicable to other pMDIs. Despite differences in
particle size distribution and aerosol plume velocity between
salbutamol and beclomethasone, performance differences be-
tween the individual aVHCs remain largely the same. Also a
different charging behavior of both drug products8 does not
affect the aVHC performance differences.
The clinical benefit of spacers and VHCs is extensively dis-
cussed by others. Rather than doubting this benefit, health care
workers should be aware of the far-reaching non-
interchangeability of VHCs, including their antistatic counter-
parts. Although this noninterchangeability of VHCs is well
recognized,1,2 aVHCs are often considered a homogeneous,
interchangeable group of devices. However, this study shows that
the antistatic properties of some aVHCs, such as the CSCþ and
IC, are suboptimal to such an extent that they are rather to be
used as ordinary nonconducting VHCs instead, and that
switching between aVHCs should be discouraged.
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MATERIALS AND METHODS
Five antistatic valved holding chambers (aVHCs) of similar
size and shape were obtained through a local pharmacy. These
are the Aerochamber Plus Flow-Vu (ACþFV), the Compact
Space Chamber Plus (CSCþ), the InspiraChamber (IC), the
OptiChamber Diamond (OCD), and the Vortex (Vortex,
Figure E1). Characteristics of these aVHCs, such as their man-
ufacturers and dimensions, are summarized in Table E1. Because
the type of drug may affect its sensitivity to static charge, a sal-
butamol pressurized metered dose inhaler (pMDI) (Ventolin 100
mg/dose label claim; GlaxoSmithKline, Brentford, UK) and a
beclomethasone dipropionate pMDI (Qvar 100 mg/dose label
claim; Teva, Petah Tikva, Israel) were used. The salbutamol
pMDI contains a suspension, whereas the beclomethasone
pMDI contains a solution. Each aVHC and each pMDI were
tested in 4-fold (n ¼ 4).
Cleaning of the aVHCs
To study whether the performance difference between the
aVHCs is caused by a difference in their antistatic behavior, 2
different aVHC cleaning procedures were compared. First, the
aVHCs were disassembled into their separate parts and soaked in
a lukewarm mild detergent solution for 15 minutes. A normal
household detergent was used in an uncontrolled concentration
(roughly suitable for dishwashing), as the type and concentration
of the detergent do not determine its antistatic effect.E1 Hereafter
the parts were dried to air in vertical position either directly (ie,
“drip-dried”) or after rinsing with water (ie, “rinsed”). Rinsing is
instructed by the manufacturers of the aVHCs and results in
testing of the aVHCs’ intrinsic antistatic properties. Drip-drying
on the other hand is expected to result in a uniform detergent
coating across the aVHCs, thereby giving them the same anti-
static properties. Cleaning by either rinsing or drip-dying of the
aVHCs was performed before each individual measurement.
Dose collection
The delivered doses from the pMDIs or the pMDI-aVHC
combinations were determined with the dose collection appa-
ratus described in the European Pharmacopoeia.E2 A flow rate of
30 L/minute was drawn through the apparatus for a total volume
of 4 L and the aerosols were collected in glass fiber filters. The
salbutamol pMDI was shaken vigorously for 5 seconds before
every actuation to homogenize the suspension, whereas the
beclomethasone pMDI with a solution was used without
shaking. The first 10 doses, as well as every dose before a mea-
surement, were discharged to waste to prime the pMDIs. A
single measurement consisted of 10 (salbutamol) or 5 actuations
(beclomethasone). A delay of at least 30 seconds between every
actuation was applied to prevent the pMDI nozzles from
freezing. A 2-second delay was applied between actuation of the
pMDIs into an aVHC and the onset of the simulated inhalation
maneuver.
The delivered dose from a pMDI may lower with increasing
dose number, especially for pMDIs that contain a suspension.E3
To enable the correction for such a drift in delivered dose,
delivered dose measurements with an aVHC were always per-
formed in between 2 measurements with a pMDI alone. The
delivered dose from the aVHC was subsequently calculated
relative to the average of the delivered doses from the pMDIalone determined directly before and after. This way, any per-
formance variations of the pMDIs will not reflect in the per-
formance of the aVHCs. Single measurements with all 5 aVHCs
were always performed on the same day so as to minimize
variation between the aVHCs due to differences in environ-
mental conditions during the experiments.
Sample preparation and analysis
Samples were collected by rinsing the dose collection appa-
ratus and soaking the glass fiber filter with water (salbutamol) or
ethanol (beclomethasone) and consecutively passing the solutions
through a 0.2-mm membrane filter to remove any suspended
glass fibers. The filtrate was then analyzed spectrophotometrically
at 225 (salbutamol) or 239 nm (beclomethasone) with a Unicam
UV 500 (ThermoSpectronic, Cambridge, UK).
Laser diffraction analysis
The particle size distributions of the aerosols directly from the
pMDIs or delivered via “rinsed” aVHCs were measured by laser
diffraction analysis with the HELOS BF and INHALER 2000
adaptor (Sympatec, Clausthal Zellerfeld, Germany). A flow rate
of 30 L/minute was applied by means of a venturi flow-pressure
indicator. Actuation procedures for the pMDIs were as described
for the determination of the delivered dose. To exclude any in-
fluence of the aerosol propellant on the particle size distributions,
data of the inner 9 detector rings were excluded by means of the
“forced stability” setting. Results are the average of 5 measure-
ments (n ¼ 5).
Aerosol imaging
Aerosol plumes from the salbutamol and beclomethasone
pMDIs were imaged using a Phantom VEO-E 310L high-speed
camera (Vision Research) equipped with a 24-85 mm lens
(Nikon, Tokyo, Japan). The aerosol was lighted with a 12,000
lm led light from below. The aerosol was filmed at 240 frames
per second, and the 12th frame at 0.05 seconds after first exit of
the aerosol from the mouthpiece was taken for an indication
about the aerosol shape and velocity.
Statistical analysis
Statistical tests were performed with Microsoft Excel 2010.
Equality of variance was tested by means of the F test.
Depending on the outcome of the F test, a homoscedastic or
heteroscedastic 2-tailed Student’s t test was performed to deter-
mine the statistical significance of any differences in the mean
delivered doses.
RESULTS
The delivered doses of the salbutamol and beclomethasone
pMDIs across the dose numbers used for the experiments in this
study are presented in Figure E2. Despite vigorous shaking
during 5 seconds before every actuation, a drift in delivered dose
with increasing dose number occurs for the suspension pMDI
(salbutamol) from around 100% to 76% of the label claim. The
solution pMDI (beclomethasone) on the other hand shows a
trend of slightly increasing delivered dose from 71% to 79% of
the label claim. The delivered dose of the beclomethasone pMDI
is generally lower than that of the salbutamol pMDI, because its
label claim refers to the metered (ex-valve) dose, whereas that of
the salbutamol pMDI refers to the delivered (ex-mouthpiece)
dose.
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aerosol is emitted from the beclomethasone pMDI than from
the salbutamol pMDI with d50 values of 1.86 and 3.05 mm,
respectively (Table E2). The use of an aVHC generally lowers
the d50 value of the inhaled aerosols, with the exception of
the Vortex aVHC in combination with the beclomethasone
pMDI.
Images of the aerosols from the salbutamol and beclometha-
sone pMDIs after 0.05 seconds are shown in Figure E3. TheTABLE E1. Overview and characteristics of the aVHCs tested
Valved holding chamber Abbreviation Manufacture
Aerochamber Plus Flow-Vu ACþFV Trudell Medical Internatio
Compact Space Chamber Plus CSCþ Medical Developments Int
InspiraChamber IC InspiRx Inc., Lupin Pharm
OptiChamber Diamond OCD Philips Respironics Inc.
Vortex Vortex PARI Respiratory Equipm
aVHC, Antistatic valved holding chamber; NA, not available.
TABLE E2. The median diameter (d50) and fine particle fraction
<5 mm (FPF) determined by laser diffraction analysis for the
pMDIs alone (no aVHC) and in combination with different aVHCs
(n ¼ 5)
Salbutamol Beclomethasone
d50, mm (SD) FPF, % (SD) d50, mm (SD) FPF, % (SD)
No aVHC 3.05 (0.12) 86.13 (2.03) 1.86 (0.06) 98.17 (2.29)
ACþFV 2.81 (0.02) 88.94 (2.23) 1.42 (0.05) 100 (0.00)
CSCþ 2.61 (0.09) 93.88 (0.82) 1.41 (0.12) 99.97 (0.07)
IC 2.75 (0.04) 91.41 (1.42) 1.43 (0.06) 100 (0.00)
OCD 2.82 (0.10) 89.63 (0.78) 1.34 (0.06) 100 (0.00)
Vortex 2.84 (0.14) 87.19 (2.61) 1.86 (0.06) 100 (0.00)
ACþFV, Aerochamber Plus Flow-Vu; aVHC, antistatic valved holding chamber;
CSCþ, Compact Space Chamber Plus; IC, InspiraChamber; OCD, OptiChamber
Diamond; pMDI, pressurized metered dose inhaler; SD, standard deviation.aerosol of the salbutamol pMDI exits as a jet that starts
expanding only after approximately 15 cm and reaches to
roughly 30 cm from the mouthpiece of the pMDI after 0.05
seconds, whereas the aerosol from the beclomethasone pMDI
starts expanding within the first 10 cm and reaches to around 20
cm from the mouthpiece in the same time. The salbutamol
aerosol therefore exits at a higher velocity than the beclometha-
sone aerosol. This is in line with the higher “plume impact force”
for the salbutamol pMDI reported by Gabrio et al.E4r Material Dimensions
nal Charge dissipative plastic polymer 14.5  4.6 cm
149 mL
ernational Charge dissipative plastic polymer 14.5  NA cm
160 mL
aceuticals Inc. Charge dissipative plastic polymer NA
Charge dissipative plastic polymer 15  5.5 cm
140 mL
ent, Inc. Aluminum 15.7  5.4 cm
NA mL
FIGURE E1. The antistatic valved holding chambers tested in this
study: Aerochamber Plus Flow-Vu (ACþFV), Compact Space
Chamber Plus (CSCþ), InspiraChamber (IC), OptiChamber Dia-
mond (OCD), and Vortex (Vortex).
FIGURE E2. Delivered doses of salbutamol (Ventolin) and beclomethasone (Qvar) without the use of a VHC across the range of dose
numbers used in this study (n ¼ 5). Each experiment with an aVHC was performed in between 2 consecutive data points, after which the
delivered dose from the aVHC was calculated relative to the average of these 2 points. aVHC, Antistatic valved holding chamber.
FIGURE E3. Plumes of the salbutamol pMDI (Ventolin, A) and
beclomethasone pMDI (Qvar, B) imaged 0.05 seconds after
emission by means of a high-speed camera. The white marks are
spaced 10 cm apart (ie, a total length of approximately 30 cm
from the pMDI mouthpieces is imaged). pMDI, Pressurized
metered dose inhaler.
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